var data={"title":"Valacyclovir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Valacyclovir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7134?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">see &quot;Valacyclovir: Drug information&quot;</a> and <a href=\"topic.htm?path=valacyclovir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Valacyclovir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232799\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Valtrex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50788690\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Valtrex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1041673\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent, Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1041707\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">see &quot;Valacyclovir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes labialis (cold sores), treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Immunocompetent</i>: Children &ge;12 years and Adolescents: Oral: 2,000 mg every 12 hours for 1 day (2 doses); initiate at earliest symptom onset</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive</i>: Adolescents: Oral: 1,000 mg twice daily for 5 to 10 days (HHS [adult OI 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes simplex virus (HSV), genital infection; <i>immuncompetent</i> patients</b>: Limited data available<b>: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>First episode; treatment: </i>Children and Adolescents: Oral: 20 <b>mg/kg</b>/dose twice daily, maximum dose: 1,000 mg/dose; for 7 to 10 days (Bradley 2017; CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Recurrent episodes; treatment:</i> Begin with onset of symptoms (prodrome) or lesion appearance (CDC [Workowski 2015]): Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;50 kg: Oral: 20 <b>mg/kg</b>/dose twice daily; maximum dose: 1,000 mg/dose; for 5 days (Bradley 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;50 kg: Oral: 1,000 mg once daily for 5 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Suppressive therapy:</i> Children and Adolescents: Oral: 20 <b>mg/kg</b>/dose once daily; maximum dose: 1,000 mg/dose (Bradley 2017; CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes simplex virus (HSV), prophylaxis i</b>\n      <b>n <i>immunocompromised</i> patients (eg, HSCT or leukopenic oncology patients):</b> Limited data available (Erard 2007; IDSA [Tomblyn 2009]): Children and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Early reactivation prevention: </i>Begin at initiation of conditioning and continue until engraftment or resolution of mucositis (IDSA [Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;40 kg: 250 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;40 kg: 500 mg once or twice daily; twice daily dosing should be considered in patients who are highly suppressed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Late reactivation prevention: </i>Continue throughout the first year following HSCT (Erard 2007; IDSA [Tomblyn 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;40 kg: 250 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;40 kg: 500 mg once or twice daily; twice daily dosing should be considered in patients who are highly suppressed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes simplex virus (HSV), treatment of acute retinal disease; step-down therapy: </b>Limited data available: Children &ge;50 kg or Adolescents: Oral: 1,000 mg 3 times daily for 4 to 6 weeks; begin after completion of a 10 to 14 day intravenous acyclovir course (HHS [adult OI 2017, pediatric OI 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes simplex virus (HSV), treatment of mucocutaneous infection or gingivostomatitis; <i>immunocompetent</i> patients:</b> Limited data available: Infants &ge;3 months, Children, and Adolescents: Oral: 20 <b>mg/kg</b>/dose twice daily for 5 to 7 days; maximum dose: 1,000 mg/dose (Bradley 2017; Kimberlin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Mononucleosis (Epstein-Barr virus [EBV]); treatment:</b> Limited data available; efficacy results variable: Adolescents: 1,000 mg 3 times daily; a small trial in college-aged students (age &ge;18 years) showed a 14-day course of valacyclovir reduced EBV oral excretion (Balfour 2007; Bradley 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Varicella (chickenpox), prophylaxis in <i>immunocompromised </i>patients (eg, HSCT or leukopenic oncology):</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed: Oral: 15 to 30 <b>mg/kg</b>/dose 3 times daily (Bomgaars 2008; Nadal 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;40 kg: Oral: 250 or 500 mg twice daily (Erard 2007; IDSA [Tomblyn 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;40 kg: Oral: 500 mg twice daily (Erard 2007; IDSA [Tomblyn 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Post</i>\n      <i>exposure prophylaxis </i>(IDSA [Tomblyn 2009]): <b>Note:</b> Continue for 22 days postexposure.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;40 kg: Oral: 500 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;40 kg: Oral: 1,000 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Varicella (chickenpox), treatment in <i>immunocompetent</i> patients: Note:</b> Routine use in otherwise healthy children not generally recommended; treatment of varicella may be considered in individuals at high risk for a possible moderate-severe course (eg, unvaccinated adolescents, individuals with chronic cutaneous or pulmonary conditions, patients on long-term salicylate therapy or receiving short, intermittent, or aerosolized corticosteroids (<i>Red Book</i> [AAP 2015]): Infants &ge;3 months, Children, and Adolescents &lt;18 years: Limited data available in patients &lt;2 years of age: Oral: 20<b> mg/kg</b>/dose 3 times daily for 5 days; maximum dose: 1,000 mg/dose; initiate within 24 hours of rash onset (Bradley 2017; <i>Red Book</i> [AAP 2015]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes labialis (cold sores):</b> Oral: 2,000 mg every 12 hours for 1 day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes zoster (shingles):</b> Oral: Immunocompetent patients: 1,000 mg 3 times daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes simplex virus (HSV), genital infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial episode:</i> Immunocompetent patients: 1,000 mg twice daily for 10 days. <b>Note:</b> CDC STD guidelines recommend a treatment duration of 7 to 10 days (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Recurrent episode:</i> Immunocompetent patients: 500 mg twice daily for 3 days or alternatively, 1,000 mg once daily for 5 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Reduction of transmission:</i> 500 mg once daily (source partner)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Suppressive therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immunocompetent patients: 1,000 mg once daily (500 mg once daily in patients with &le;9 recurrences per year). <b>Note:</b> Safety and efficacy have been documented for up to 1 year (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-infected patients (CD4 &ge;100 cells/mm<sup>3</sup>): 500 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes labialis:</b> Adolescents and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 49 mL/minute: 1,000 mg every 12 hours for 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 29 mL/minute: 500 mg every 12 hours for 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: 500 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes zoster:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 49 mL/minute: 1,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 29 mL/minute: 1,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Genital herpes:</b> Adolescents and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial episode:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute: 1,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recurrent episode: CrCl &le;29 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suppressive therapy: CrCl &le;29 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For usual dose of 1,000 mg every 24 hours, decrease dose to 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For usual dose of 500 mg every 24 hours, decrease dose to 500 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-infected patients: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Dialyzable (~33% removed during 4-hour session); administer dose postdialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>Children &ge;2 years, Adolescents, and Adults: No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232774\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valtrex: 500 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valtrex: 1 g [scored; contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 1 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232759\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1041713\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May administer with or without food</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232795\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1041674\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of herpes labialis (cold sores) (FDA approved in ages &ge;12 years and adults); treatment of chickenpox in immunocompetent patients (FDA approved in ages 2 to &lt;18 years); treatment of herpes zoster (shingles) in immunocompetent patients (FDA approved in adults); treatment of initial and recurrent episodes of genital herpes (FDA approved in adults); suppression of recurrent genital herpes and reduction of heterosexual transmission of genital herpes in immunocompetent patients (FDA approved in adults); has also been used for suppression of genital herpes and the treatment of mononucleosis (Epstein-Barr virus)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232826\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valtrex may be confused with Keflex, Valcyte, Zovirax</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ValACYclovir may be confused with acyclovir, valGANciclovir, vancomycin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232824\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Depression, dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea (more common in children), nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysmenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Thrombocytopenia, leukopenia (mild)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Herpes simplex infection (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasopharyngitis, rhinorrhea (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Aggressive behavior, agitation, alopecia, anemia, aplastic anemia, ataxia, brain disease, coma, confusion, delirium, dysarthria, erythema multiforme, facial edema, hallucination (auditory and visual), hemolytic-uremic syndrome, hepatitis, hypersensitivity reaction (acute; includes anaphylaxis, angioedema, dyspnea, pruritus, skin rash, urticaria), hypertension, hypersensitivity angiitis, increased serum creatinine, loss of consciousness, mania, psychosis, renal failure, renal pain, seizure, skin photosensitivity, tachycardia, thrombotic thrombocytopenic purpura, tremor, urinary urgency, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232781\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to valacyclovir, acyclovir, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232763\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: CNS adverse effects (including agitation, hallucinations, confusion, delirium, seizures, and encephalopathy) have been reported in both adult and pediatric patients with or without renal dysfunction. Elderly patients are more likely to experience CNS adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Has occurred in immunocompromised patients (at doses of 8 g/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment, the elderly, and/or those receiving nephrotoxic agents. Acute renal failure and CNS effects have been observed in patients with renal dysfunction; dose adjustment may be required. Precipitation in renal tubules may occur; maintain adequate hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; CNS effects have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunocompromised patients: Advanced HIV (CD4 &lt;100 cells/mm<sup>3</sup>): Safety and efficacy have not been established for treatment/suppression of recurrent genital herpes or disseminated herpes in patients with profound immunosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For cold sores, treatment should begin with earliest symptom (tingling, itching, burning). For genital herpes, treatment should begin as soon as possible after the first signs and symptoms (within 72 hours of onset of first diagnosis or within 24 hours of onset of recurrent episodes). For herpes zoster, treatment should begin within 72 hours of onset of rash. For chickenpox, treatment should begin with earliest sign or symptom.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819281\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">CNS adverse events (eg, agitation, hallucinations, confusion, delirium, seizures, and encephalopathy) have been reported in children with and without renal dysfunction receiving doses exceeding those recommended for current renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300201\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232768\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13001&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Acyclovir-Valacyclovir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Acyclovir-Valacyclovir may increase the serum concentration of Mycophenolate. Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Acyclovir-Valacyclovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus Vaccine: Acyclovir-Valacyclovir may diminish the therapeutic effect of Varicella Virus Vaccine.  Management: When possible, avoid use of acyclovir or valacyclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of these antiviral agents for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Acyclovir-Valacyclovir may enhance the CNS depressant effect of Zidovudine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zoster Vaccine (Live/Attenuated): Acyclovir-Valacyclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated).  Management: When possible, discontinue antiviral agents with anti-zoster activity (i.e., acyclovir, valacyclovir, famciclovir) for at least 24 hours prior to and 14 days after receiving a live attenuated zoster vaccine.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232770\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232784\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Valacyclovir is metabolized to acyclovir. In a pharmacokinetic study, maternal acyclovir serum concentrations were higher in pregnant women receiving valacyclovir than those given acyclovir for the suppression of recurrent herpes simplex virus (HSV) infection late in pregnancy. Amniotic fluid concentrations were also higher; however, there was no evidence that fetal exposure differed between the groups (Kimberlin 1998). Data from an acyclovir pregnancy registry has shown no increased rate of birth defects than that of the general population; however, the registry is small and the manufacturer notes that use during pregnancy is only warranted if the potential benefit to the mother justifies the risk of the fetus. Because more data is available for acyclovir, that agent is preferred for the treatment of genital herpes in pregnant women (CDC [Workowski 2015]); however, valacyclovir may be considered for use due to its simplified dosing schedule (HHS [OI adult 2015]). Pregnant women who have a history of genital herpes recurrence, suppressive therapy is recommended starting at 36-weeks gestation (HHS [OI adult 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1041715\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinalysis, BUN, serum creatinine, liver enzymes, CBC</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232762\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Valacyclovir is rapidly and nearly completely converted to acyclovir by intestinal and hepatic metabolism. Acyclovir is converted to acyclovir monophosphate by virus-specific thymidine kinase then further converted to acyclovir triphosphate by other cellular enzymes. Acyclovir triphosphate inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and being incorporated into viral DNA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232780\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Acyclovir is widely distributed throughout the body including brain, kidney, lungs, liver, spleen, muscle, uterus, vagina, and CSF </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~14% to 18%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; valacyclovir is rapidly and nearly completely converted to acyclovir and L-valine by first-pass effect; acyclovir is hepatically metabolized to a very small extent by aldehyde oxidase and by alcohol and aldehyde dehydrogenase (inactive metabolites) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~55% once converted to acyclovir </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Normal renal function: Children: 1.3 to 2.5 hours, slower clearance with increased age; Adults: Acyclovir: 2.5-3.3 hours, Valacyclovir: ~30 minutes; End-stage renal disease: Acyclovir: 14 to 20 hours; During hemodialysis: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Children: 1.4 to 2.6 hours; Adults: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine, primarily as acyclovir (89%); <b>Note:</b> Following oral administration of radiolabeled valacyclovir, 46% of the label is eliminated in the feces (corresponding to nonabsorbed drug), while 47% of the radiolabel is eliminated in the urine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597900\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">C<sub>max</sub> ~4.2 mcg/mL in children 1 month to &lt;12 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6869964\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nadal (2002) suggests the following dosage equivalency:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">30 mg/kg/dose 3 times/day valacyclovir corresponds to IV acyclovir 250 mg/m<sup>2</sup> or 10 mg/kg/dose 3 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">20 mg/kg/dose 3 times/day valacyclovir corresponds to oral acyclovir 20 mg/kg 4-5 times/day </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eksborg, et al (2002) suggests the following dosage equivalency: 500 mg valacyclovir equivalent to 349 mg of  IV acyclovir</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6825106\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>50 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 50 mg/mL oral suspension may be made with caplets and either Ora-Sweet or Ora-Sweet SF. Crush eighteen 500 mg caplets in a mortar and reduce to a fine powder. Add 5 mL portions of chosen vehicle (40 mL total) and mix to a uniform paste; transfer to a 180 mL calibrated amber glass bottle, rinse mortar with 10 mL of vehicle 5 times, and add quantity of vehicle sufficient to make 180 mL. Label &quot;shake well&quot; and &quot;refrigerate.&quot; Stable for 21 days refrigerated.</p>\n    <div class=\"reference\">Fish DN, Vidaurri VA, and Deeter RG, &quot;Stability of Valacyclovir Hydrochloride in Extemporaneously Prepared Oral Liquids,&quot; <i>Am J Health Syst Pharm</i>, 1999, 56(19):1957-60.<span class=\"pubmed-id\">10554914</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232783\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (ValACYclovir HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (30): $379.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $216.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Valtrex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (30): $751.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (90): $1,288.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232787\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alaclov (BD);</li>\n      <li>Herclov (ID);</li>\n      <li>Iclofar (ID);</li>\n      <li>Inclovir (ID);</li>\n      <li>Ovalac (BD);</li>\n      <li>Rapivir (CR, DO, GT, HN, MX, NI, PA, SV, UY);</li>\n      <li>Revira (BD);</li>\n      <li>Rivacir (HU);</li>\n      <li>Shilova (AU);</li>\n      <li>Talavir (IT);</li>\n      <li>Vaciclor (SG);</li>\n      <li>Vaclovir (AU);</li>\n      <li>Vacyless (TW);</li>\n      <li>Vadiral (CO);</li>\n      <li>Valaclor (KR);</li>\n      <li>Valarux (BD);</li>\n      <li>Valasil (KR);</li>\n      <li>Valcivir (IN);</li>\n      <li>Valcyclor (CO);</li>\n      <li>Valextra (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Valotix (IE);</li>\n      <li>Valovir (ET, SG, ZW);</li>\n      <li>Valraci (KR);</li>\n      <li>Valtcro (KR);</li>\n      <li>Valtra (HK, KR);</li>\n      <li>Valtrex (AE, AR, AT, AU, BB, BD, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CY, CZ, DE, EC, EE, EG, ES, FI, GB, GR, GY, HK, ID, IE, IL, IQ, IR, IS, JM, JO, JP, KR, KW, LB, LT, LV, LY, MT, MY, NO, NZ, OM, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SR, SY, TH, TR, TT, TW, VE, YE);</li>\n      <li>Valvir (AU, ID, LK, SG);</li>\n      <li>Viranet (AR);</li>\n      <li>Zelitrex (AU, BE, DK, FR, NL, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins, &quot;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. No. 82 June 2007. Management of Herpes in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2007, 109(6):1489-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17569194/pubmed\" target=\"_blank\" id=\"17569194\">17569194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;ACOG Practice Bulletin. Management of Herpes in Pregnancy. Number 8 October 1999. Clinical Management Guidelines For Obstetrician-Gynecologists,&quot; <i>Int J Gynaecol Obstet</i>, 2000, 68(2):165-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/10717827/pubmed\" target=\"_blank\" id=\"10717827\">10717827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balfour HH Jr, Hokanson KM, Schacherer RM, et al, &quot;A Virologic Pilot Study of Valacyclovir in Infectious Mononucleosis,&quot; <i>J Clin Virol</i>, 2007, 39(1):16-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17369082/pubmed\" target=\"_blank\" id=\"17369082\">17369082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bomgaars L, Thompson P, Berg S, et al, &quot;Valacyclovir and Acyclovir Pharmacokinetics in Immunocompromised Children,&quot; <i>Pediatr Blood Cancer</i>, 2008, 51(4):504-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/18561175/pubmed\" target=\"_blank\" id=\"18561175\">18561175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drake AL, Roxby AC, Kiarie J, et al. Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial. <i>PLoS One</i>. 2012;7(4):e34635.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/22509337/pubmed\" target=\"_blank\" id=\"22509337\">22509337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eksborg S, Pal N, Kalin M, et al, &quot;Pharmacokinetics of Acyclovir in Immunocompromized Children With Leukopenia and Mucositis After Chemotherapy: Can Intravenous Acyclovir Be Substituted by Oral Valacyclovir?&quot; <i>Med Pediatr Oncole</i>, 2002, 38(4):240-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/11920787/pubmed\" target=\"_blank\" id=\"11920787\">11920787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. <i>Blood</i>. 2007;110(8):3071-3077.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17515400/pubmed\" target=\"_blank\" id=\"17515400\">17515400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fish DN, Vidaurri VA, and Deeter RG, &quot;Stability of Valacyclovir Hydrochloride in Extemporaneously Prepared Oral Liquids,&quot; <i>Am J Health Syst Pharm</i>, 1999, 56(19):1957-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/10554914/pubmed\" target=\"_blank\" id=\"10554914\">10554914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov%20/\" target=\"_blank\">http://aidsinfo.nih.gov </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations From the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Available at: <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a>. December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaiyeoba O, Amaya MI, Soper DE, et al, &quot;Preventing Neonatal Transmission of Herpes Simplex Virus,&quot; <i>Clin Obstet Gynecol</i>, 2012, 55(2):510-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/22510634/pubmed\" target=\"_blank\" id=\"22510634\">22510634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Jacobs RF, Weller S, et al, &quot;Pharmacokinetics and Safety of Extemporaneously Compounded Valacyclovir Oral Suspension in Pediatric Patients From 1 Month Through 11 years of Age,&quot; <i>Clin Infect Dis</i>, 2010, 50(2):221-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/20014952/pubmed\" target=\"_blank\" id=\"20014952\">20014952</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DF, Weller S, Whitley RJ, et al, &quot;Pharmacokinetics of Oral Valacyclovir and Acyclovir in Late Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 1998, 179(4):846-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/9790357/pubmed\" target=\"_blank\" id=\"9790357\">9790357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nadal D, Leverger G, Sokal EM, et al, &ldquo;An Investigation of the Steady-State Pharmacokinetics of Oral Valacyclovir in Immunocompromised Children,&rdquo; <i>J Infect Dis</i>, 2002, 186(Suppl 1):S123-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12353197/pubmed\" target=\"_blank\" id=\"12353197\">12353197</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sheffield JS, Fish DN, Hollier LM, Cadematori S, Nobles BJ, Wendel GD Jr. Acyclovir concentrations in human breast milk after valaciclovir administration. <i>Am J Obstet Gynecol</i>. 2002;186(1):100-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/11810093/pubmed\" target=\"_blank\" id=\"11810093\">11810093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simon MW, Fish DN, and Deeter RG, &ldquo;Pharmacokinetics and Safety of Valaciclovir in Children With Epstein-Barr Virus Illness,&rdquo; <i>Drugs R D</i>, 2002, 3(6):365-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12516939/pubmed\" target=\"_blank\" id=\"12516939\">12516939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valtrex (valacyclovir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13001 Version 204.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F232799\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50788690\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1041673\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1041707\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F232774\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F232759\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1041713\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F232795\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1041674\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F232826\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F232824\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F232781\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F232763\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819281\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300201\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F232768\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F232770\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F232784\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1041715\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F232762\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F232780\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597900\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F6869964\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F6825106\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F232783\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F232787\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13001|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir: Drug information</a></li><li><a href=\"topic.htm?path=valacyclovir-patient-drug-information\" class=\"drug drug_patient\">Valacyclovir: Patient drug information</a></li></ul></div></div>","javascript":null}